Tag Archives: Iovance Biotherapeutics Inc

H.C. Wainwright Believes Iovance Biotherapeutics Inc (NASDAQ: IOVA) Won’t Stop Here

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Iovance Biotherapeutics Inc (IOVA – Research Report), with a price target of $26. The company’s shares closed yesterday at $16.63, close to its 52-week high

Iovance Biotherapeutics Inc (IOVA) Gets a Buy Rating from Oppenheimer

Oppenheimer analyst Mark Breidenbach maintained a Buy rating on Iovance Biotherapeutics Inc (IOVA – Research Report) yesterday and set a price target of $25. The company’s shares closed yesterday at $11.80. Breidenbach wrote: “Tuesday, we attended Iovance meetings with institutional

Iovance Biotherapeutics Inc (IOVA) Gets a Buy Rating from Chardan Capital

Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Iovance Biotherapeutics Inc (IOVA – Research Report) today and set a price target of $20. The company’s shares opened today at $9.80. According to TipRanks.com, Livshits is a 1-star analyst

H.C. Wainwright Keeps a Buy Rating on Iovance Biotherapeutics Inc (IOVA)

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Iovance Biotherapeutics Inc (IOVA – Research Report) today and set a price target of $26. The company’s shares opened today at $9.65. Pantginis said: “Valuation and impediments to achieving price

Chardan Capital Reaffirms Their Buy Rating on Iovance Biotherapeutics Inc (IOVA)

In a report released today, Gbola Amusa from Chardan Capital reiterated a Buy rating on Iovance Biotherapeutics Inc (IOVA – Research Report), with a price target of $20. The company’s shares closed yesterday at $10.65. Amusa observed: “We expect more

Oppenheimer Remains a Buy on Iovance Biotherapeutics Inc (IOVA)

In a report released today, Mark Breidenbach from Oppenheimer maintained a Buy rating on Iovance Biotherapeutics Inc (IOVA – Research Report), with a price target of $25. The company’s shares closed yesterday at $9.38. Breidenbach noted: “Wednesday, we sat down